Page values for "Linaclotide"

Nav

"Medicines" values

1 row is stored for this page

Field	Field type	Value
generic	`String`	Linaclotide
brand	`String`	Linzess
structure	`File`
classes	List of `String`, delimiter: `,`	[[:Category:Guanylate_cyclase_C_agonists\|Guanylate cyclase-C agonist]] • [[:Category:IBS_treatments\|IBS-C treatment]]
mechanism	`String`	'"`UNIQ--vote-00001197-QINU`"' Extracellular cGMP separately activates submucosal sensory afferents in a way that reduces visceral pain perception, distinguishing linaclotide from purely osmotic laxatives in IBS-C. Diarrhea is the dose-limiting effect'"`UNIQ--ref-00001198-QINU`"'.
uses	`String`	'"`UNIQ--vote-00001199-QINU`"', '"`UNIQ--vote-0000119A-QINU`"', '"`UNIQ--vote-0000119B-QINU`"'
starting_dose	`String`	145 mcg PO once daily for chronic idiopathic constipation; 290 mcg daily for IBS-C; pediatric 72 mcg daily
preparations	`String`	72, 145, 290 mcg capsules
fda_max	`String`	290 mcg/d
pill_id	`Text`
routes	List of `String`, delimiter: `,`	Oral
onset	`String`	Bowel movement within 1 week; abdominal pain improvement over weeks
duration	`String`	24 hours
halflife	`String`	Not meaningfully described (negligible systemic absorption — the drug acts locally and is degraded in the GI tract)'"`UNIQ--ref-0000119C-QINU`"'
bioavailability	`String`	Negligible systemic absorption'"`UNIQ--ref-0000119D-QINU`"'
pregnancy	`String`	Limited data; minimal systemic absorption likely renders fetal risk low.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed\|citation needed]]]</sup>
legal	`String`	[[USLegal:Prescription only\|Rx-only]] in US. Carries a '''Boxed Warning''' contraindicating use in children <2 years (lethal dehydration in animal studies)'"`UNIQ--ref-0000119E-QINU`"'